Literature DB >> 227926

Prostaglandin E modulation of the mitogenic response of human T cells. Differential response of T-cell subpopulations.

J D Stobo, M S Kennedy, M E Goldyne.   

Abstract

Prostaglandins (PG) of the E series, PGE(1) and PGE(2) (PGEs), can induce elevations of intracellular cyclic AMP (cAMP) among thymus-derived (T) lymphocytes (T cells) and inhibit their reactivity. For example, 0.1 muM of PGEs induces a two- to threefold increase of intracellular cAMP among human peripheral blood T cells and a 20-30% suppression of their blastogenic response to phytohemagglutinin. However, this suppression actually represents the net reactivity of T-cell populations demonstrating quite different responses to PGEs. Fractionation of T-enriched populations on a discontinuous density gradient yields a population of high density cells whose phytohemagglutinin-induced blastogenic response is suppressed 60%; a population of intermediate density cells whose response is suppressed 20%; and a population of low density T cells whose response is not suppressed, but is enhanced 20% by both of the PGEs. The diametrically opposite responses of low and high density T cells to the PGEs is not related to any difference in their intrinsic mitogen reactivity nor is it influenced by interactions with other T cells, bone marrow-derived (B) cells, or monocytes. Moreover, the distinct blastogenic response of low and high density T cells to PGEs does not simply correlate with PGE-mediated activation of adenylate cyclase. PGE(2) induced comparable absolute and identical relative increases of intracellular cAMP among the low and high density T cells. Cholera toxin, a potent activator of adenylate cyclase, and exogenous 8-bromo cAMP mimicked the effects of the PGEs on these two T-cell populations. These data demonstrate that T cells are heterogeneous with regard to their response to the PGEs. Thus, PGEs should be considered as potential regulators rather than as universal suppressors for T-cell reactivity. Moreover, the effect of PGEs on the blastogenic response of a given T-cell population depends upon intracellular events which occur subsequent to elevations of cAMP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 227926      PMCID: PMC371263          DOI: 10.1172/JCI109572

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Selective suppression by adherent cells, prostaglandin, and cyclic AMP analogues of blastogenesis induced by different mitogens.

Authors:  A Novogrodsky; A L Rubin; K H Stenzel
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

Review 2.  Prostaglandins and the immune response.

Authors:  L M Pelus; H R Strausser
Journal:  Life Sci       Date:  1977-03-15       Impact factor: 5.037

3.  Prostaglandin regulation of macrophage collagenase production.

Authors:  L M Wahl; C E Olsen; A L Sandberg; S E Mergenhagen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

Review 4.  Prostaglandins and thromboxanes.

Authors:  B Samuelsson; M Goldyne; E Granström; M Hamberg; S Hammarström; C Malmsten
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

Review 5.  Prostaglandins: physiology, biochemistry, pharmacology and clinical applications.

Authors:  T M Elattar
Journal:  J Oral Pathol       Date:  1978-08

6.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

7.  Prostaglandins and the modulation of immunological responses.

Authors:  M E Goldyne
Journal:  Int J Dermatol       Date:  1977-11       Impact factor: 2.736

8.  Adenylate cyclase from synchronized neuroblastoma cells: responsiveness to prostaglandin E1, adenosine, and dopamine during the cell cycle.

Authors:  J Pénit; B Cantau; J Huot; S Jard
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

9.  Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes.

Authors:  T Yoneda; G R Mundy
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

10.  Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.

Authors:  J S Goodwin; A D Bankhurst; R P Messner
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

View more
  21 in total

Review 1.  The role of prostaglandins in altered leukocyte function in multiple sclerosis.

Authors:  P Dore-Duffy; S Y Ho; M Longo
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Differential sensitivity to cAMP among human cord and maternal/adult peripheral lymphocytes discloses differences between PHA- and OKT3-induced activation pathways.

Authors:  N Papadogiannakis; S A Johnsen; S Rosberg; R G Andersson; L B Olding
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

3.  Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.

Authors:  S J Hawkins; C M Black; N D Hall; A McGregor; E F Ring; P J Maddison
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

4.  Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

Authors:  M F Martin; P M Dowd; E F Ring; E D Cooke; P A Dieppe; J D Kirby
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

5.  Staphylococcal exopolysaccharides inhibit lymphocyte proliferative responses by activation of monocyte prostaglandin production.

Authors:  R D Stout; K P Ferguson; Y N Li; D W Lambe
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Cyclic AMP inhibits macrophage suppressor function and enhances lymphocyte proliferation.

Authors:  W M Gonsalkorale; M J Dascombe; I V Hutchinson
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

Review 7.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

Review 8.  Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells.

Authors:  Y Kikuchi; T Kita; J Hirata; M Fukushima
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

9.  Suppression of interleukin 2-dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGE-independent mechanism of inhibition by the fatty acids.

Authors:  D Santoli; P D Phillips; T L Colt; R B Zurier
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

10.  The inhibition of T-lymphocyte proliferation by fatty acids is via an eicosanoid-independent mechanism.

Authors:  P C Calder; S J Bevan; E A Newsholme
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.